| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
BioLineRx Ltd (NASDAQ: BLRX)
BLRX Technical Analysis
5
| As on 30th Jan 2025 BLRX SHARE Price closed @ 3.57 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 1.22 & Strong Buy for SHORT-TERM with Stoploss of 1.66 we also expect STOCK to react on Following IMPORTANT LEVELS. |
BLRXSHARE Price
| Open | 4.44 | Change | Price | % |
| High | 4.44 | 1 Day | 3.46 | 3145.45 |
| Low | 3.33 | 1 Week | 3.47 | 3470.00 |
| Close | 3.57 | 1 Month | 3.35 | 1522.73 |
| Volume | 704861 | 1 Year | 2.09 | 141.22 |
| 52 Week High 2.45 | 52 Week Low 0.10 | ||||
NASDAQ USA Most Active Stocks
| AMRS | 0.14 | 100.00% |
| NVDA | 124.65 | 0.77% |
| CLEU | 0.15 | -98.06% |
| LMDX | 0.02 | 0.00% |
| NAOV | 0.59 | 55.26% |
| KZIA | 1.90 | 37.68% |
| INTC | 20.01 | 1.32% |
| AKTS | 0.04 | 0.00% |
| TSLA | 400.28 | 2.87% |
| TNXP | 0.38 | -11.63% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| BLRX Daily Charts |
BLRX Intraday Charts |
Whats New @ Bazaartrend |
BLRX Free Analysis |
|
|
BLRX Important Levels Intraday
| RESISTANCE | 5.71 |
| RESISTANCE | 5.02 |
| RESISTANCE | 4.60 |
| RESISTANCE | 4.17 |
| SUPPORT | 2.97 |
| SUPPORT | 2.54 |
| SUPPORT | 2.12 |
| SUPPORT | 1.43 |
BLRX Forecast January 2025
| 4th UP Forecast | 5.25 |
| 3rd UP Forecast | 4.71 |
| 2nd UP Forecast | 4.38 |
| 1st UP Forecast | 4.04 |
| 1st DOWN Forecast | 3.1 |
| 2nd DOWN Forecast | 2.76 |
| 3rd DOWN Forecast | 2.43 |
| 4th DOWN Forecast | 1.89 |
BLRX Weekly Forecast
| 4th UP Forecast | 4.13 |
| 3rd UP Forecast | 3.95 |
| 2nd UP Forecast | 3.84 |
| 1st UP Forecast | 3.73 |
| 1st DOWN Forecast | 3.41 |
| 2nd DOWN Forecast | 3.30 |
| 3rd DOWN Forecast | 3.19 |
| 4th DOWN Forecast | 3.01 |
BLRX Forecast2025
| 4th UP Forecast | 11.97 |
| 3rd UP Forecast | 9.28 |
| 2nd UP Forecast | 7.61 |
| 1st UP Forecast | 5.95 |
| 1st DOWN Forecast | 1.19 |
| 2nd DOWN Forecast | -0.47 |
| 3rd DOWN Forecast | -2.14 |
| 4th DOWN Forecast | -4.83 |
BioLineRx Ltd ( NASDAQ USA Symbol : BLRX )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
BLRX Business Profile
BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of solid tumors, hematological malignancies, and stem cell mobilization; AGI-134, an immuno-oncology agent in the development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of BL-8040 with KEYTRUDA (pembrolizumab) in pancreatic cancer; and Genentech Inc. to investigate the combination of BL-8040 for solid tumors. BioLineRx Ltd. was founded in 2003 and is headquartered in Hevel Modi'in, Israel. Address: Modi?in Technology Park, Hevel Modi'in, Israel, 7177871
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service